CONRAY 325 Drug Patent Profile
✉ Email this page to a colleague
When do Conray 325 patents expire, and when can generic versions of Conray 325 launch?
Conray 325 is a drug marketed by Mallinckrodt and is included in one NDA.
The generic ingredient in CONRAY 325 is iothalamate sodium. There is one drug master file entry for this compound. Additional details are available on the iothalamate sodium profile page.
Summary for CONRAY 325
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 19 |
Patent Applications: | 600 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CONRAY 325 at DailyMed |
US Patents and Regulatory Information for CONRAY 325
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mallinckrodt | CONRAY 325 | iothalamate sodium | INJECTABLE;INJECTION | 017685-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |